Highlights

  • Cochlear reported FY26 sales Revenue of $2.3 billion, up 2% in constant currency, with second-half revenue growth of 6%
  • Underlying net profit for FY26 was $322 million, reflecting a net profit Margin of 14%, achieving the upper end of the company's revised guidance range
  • The Nucleus Nexa System reached more than 95% of developed market implant mix by June, supported by an average 3% price increase
  • Free Cash Flow more than doubled year-over-year, with Operating Cash Flow improving by $130 million

Cochlear Limited (ASX:COH) is a global manufacturer of implantable hearing solutions, including cochlear implants, bone conduction systems and related sound processors. This article reviews the company's FY26 full-year results, its core operations, sector context and developments shareholders are monitoring heading into FY27.

The share price was AUD 136.39 during the Trading session on 17 September 2026. The stock moved down by 0.62% during the trading session on 17 September 2026.

Company Business

Cochlear designs, manufactures and supplies cochlear implants, bone conduction hearing systems and related sound processors, along with associated services, for people with moderate-to-profound hearing loss. Cochlear implant systems represent the largest component of the company's sales revenue. The company sells its products in developed markets, including the United States, Western Europe and Asia Pacific, as well as in emerging markets. During FY26, Cochlear progressed the rollout of its Nucleus Nexa System, described as the first and only smart cochlear implant system with upgradeable firmware, alongside continued Investment in its product pipeline, including drug-eluting electrode technology.

Sector Context

The implantable hearing device sector is influenced by referral pathways from audiologists, general practitioners and ear, nose and throat specialists, insurance and reimbursement settings across different markets, and broader healthcare system capacity, including hospital surgical waiting lists. Market conditions vary by region, with factors such as national health service waiting lists, industrial action affecting hospital capacity, and consumer sentiment around elective procedures all cited as relevant to implant Demand in different markets during FY26. The sector also continues to see growth in direct-to-consumer Marketing approaches aimed at increasing awareness and self-referral among candidates for hearing implants.

Recent Developments

Cochlear released its FY26 full-year results for the year ended 30 June 2026 to the ASX on 18 August 2026. During the financial year, the company revised its underlying net profit guidance downward on more than one occasion, most recently in April 2026, when it reduced its guidance range to $290 million to $330 million from an initial range of $435 million to $460 million, citing softer trading conditions in developed markets, Manufacturing overhead impacts from lower production volumes, and heightened uncertainty related to conditions in the Middle East. The company also accelerated plans to reshape its cost base during the year. By the FY26 results announcement, the company reported that the Nucleus Nexa System had captured more than 95% of the developed market implant mix by June 2026.

Financial Performance

For FY26, Cochlear reported sales revenue of $2.3 billion, up 2% in constant currency, with second-half revenue growth of 6% reflecting accelerating momentum. Underlying net profit was $322 million, representing a net profit margin of 14%, at the upper end of the company's revised guidance range. Gross margin declined three percentage points to 71%. Research and Development expenses increased 15% to $323 million, representing 14% of sales revenue, up from 12% in the prior year. Reported operating expenses rose 5% to $1,251 million, including $32 million in restructuring costs and $37 million in short-term incentive provisioning, though comparable operating expenses declined 1%. Free cash flow more than doubled compared with the prior year, and operating cash flow improved by $130 million, supported by a $75 million reduction in inventory during the second half.

Risks to Consider

Cochlear's disclosures during FY26 point to risks including softer-than-expected trading conditions in developed implant markets, manufacturing overhead impacts linked to production planning, and currency movements affecting reported results given the company's global revenue base. Regional risks noted by the company include hospital capacity constraints and elective surgery backlogs in parts of Western Europe, industrial action affecting hospital operations, and competitive share pressure in certain markets. The company also flagged heightened uncertainty in the Middle East and the potential for receivables provisioning in that region as relevant factors during the year.

What to Watch Next

Shareholders are monitoring the continued rollout and market uptake of the Nucleus Nexa System, further progress on cost-base reshaping initiatives, and performance trends across developed and emerging markets into FY27. The company's ongoing investment in its product pipeline, including drug-eluting electrode technology, and its half-year results for the six months to 31 December 2026 represent further points of disclosure for investors.

Key Insights

Cochlear's FY26 results reflect a year of guidance revisions and margin pressure, with underlying net profit ultimately landing at the upper end of the company's most recent guidance range. The successful rollout of the Nucleus Nexa System and a stronger second-half revenue trajectory provide some momentum heading into FY27, alongside continued cost-base reshaping initiatives. Regional performance varied significantly, with growth in the United States and Asia Pacific offset by declines in Western Europe and emerging markets.